- Home
- PAA vs INCY Comparison
PAA vs INCY Comparison
Compare PAA & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAA | INCY |
|---|---|---|
| Founded | 1981 | 1991 |
| Country | United States | United States |
| Employees | 4200 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8B | 17.0B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | PAA | INCY |
|---|---|---|
| Price | $22.49 | $108.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | $21.83 | ★ $103.52 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | ★ 7.38% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $9.51 | $10.44 |
| Revenue Next Year | N/A | $10.99 |
| P/E Ratio | ★ $12.39 | $71.82 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $15.69 | $67.15 |
| 52 Week High | $24.26 | $112.29 |
Technical Indicators
Market Signals| Indicator | PAA | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 70.35 |
| Support Level | $22.39 | $99.10 |
| Resistance Level | $22.92 | $109.49 |
| Average True Range (ATR) | 0.46 | 3.51 |
| MACD | -0.11 | 1.15 |
| Stochastic Oscillator | 4.75 | 90.58 |
Price Performance
Historical ComparisonAbout PAA Plains All American Pipeline L.P.
Plains All American Pipeline LP, through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, barges, or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.